A potent anticancer agent from Australian company Cytopia Ltd is to enter Phase I clinical trials with thirty patients with advanced solid tumors. The synthetic compound, labeled CYT997, is a microtubule-targeting agent, and was demonstrated to be a highly effective agent against prostate, colon, breast cancer, lymphoma, and leukemia cells. Other microtubule targeting agents include paclitaxel and epothilone. The patients will receive up to six cycles of the drug by intravenous infusion once every three weeks. The primary goal is to evaluate safety and tolerability prior to Phase II clinical trials. CYT997 has also shown oral activity and the company says preliminary tests indicate that cancer cells will not readily develop resistance to this compound.
Anticancer activity down under